Seaport Therapeutics is a clinical-stage biopharmaceutical company developing medicines for depression, anxiety, and other neuropsychiatric disorders. Its proprietary Glyph platform aims to improve oral delivery of clinically validated mechanisms that have been limited by first-pass metabolism, poor bioavailability, or side effects. The company focuses on inventing oral therapies that retain established efficacy and safety profiles while addressing those historical limitations.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 0 | — | -13.1 | — |
| Q1 2026 | 0 | — | -25.4 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Upbound Group, Inc. (UPBD), SharonAI Holdings Inc. (SHAZ), Orion180 Insurance Group Inc. (OIG), Camden National Corporation (CAC), NWPX Infrastructure, Inc. (NWPX), POET Technologies Inc. (POET)